These in vivo results demonstrate that TRPV4 hyperactivation exacerbates atherosclerosis by promoting inflammation and NLRP3 activation, whereas its inhibition confers strong protection, establishing TRPV4 as a key mechanistic target for treatment. This evidence concerns the gene NLRP3 and atherosclerosis.